Multicenter, Open-label, Uncontrolled Study to Investigate Suppression of Ovarian Activity of a Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in 80 Young Female Volunteers Over 3 Treatment Cycles
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Ethinylestradiol/gestodene (Primary)
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Bayer
- 19 Sep 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Sep 2015 Status changed from not yet recruiting to recruiting,as reported by ClinicalTrials.gov.